Lexington Biosciences, Inc. is a medical device company, which engages in the research and development of non-diagnostic devices. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2017-06-01. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The firm is in the final stages of releasing the developed product for clinical studies. The firm's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.
Follow-Up Questions
LXGTF 주식의 가격 성능은 어떻습니까?
LXGTF의 현재 가격은 $0.0001이며, 전 거래일에 decreased 0% 하였습니다.
Lexington Biosciences Holdings Corp의 주요 사업 주제나 업종은 무엇입니까?
Lexington Biosciences Holdings Corp은 N/A 업종에 속하며, 해당 부문은 N/A입니다
Lexington Biosciences Holdings Corp의 시가총액은 얼마입니까?
Lexington Biosciences Holdings Corp의 현재 시가총액은 $378.684입니다
